Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2002

View Archived Issues

Merck & Co. outlines new cycle of breakthrough medicines at San Francisco conference

Amylin concentrating its efforts on two late-stage, first-in-class products

Antisense oligodeoxynucleotide targeting Bid inhibits bile acid-induced liver injury

Novel class of potent and selective 5-HT1A ligands designed at Servier

Biogen highlights two superstar candidates from robust pipeline

Access Oncology obtains rights to noncardiotoxic anthracyclines

Acorda chooses spasticity as fampridine lead indication

Antisense anticancer agent achieves clinical milestone

Cyclic glycopeptide antibiotics discovered to have attractive properties at Wyeth-Ayerst

Highly immunogenic malaria vaccine candidate heads for the clinic

Antex extends manufacturing agreement for vaccines

Neurotech licenses Amgen's CNTF for ophthalmic indications

InFUSE Bone Graft recommended for approval for spinal fusion by FDA panel

ComGenex and Solvo file patent application for drug candidates from collaboration

CollaGenex expands into dermatology

Positive results from phase II trial of SomatoKine in type 2 diabetes

Eos transfers lead antibody target to Pharmacopeia; companies in the process of merging

PhotoCure submits MAA for Metvix PDT in Switzerland

Disappointing preliminary results from first phase III trial of INS-3 Ophthalmic in dry eye

Keryx licenses novel technology for small-molecule drug design

New series of PARP inhibitors and their potential therapeutic uses described by Guilford

Cholecystokin and gastrin receptor ligands in development at James Black Foundation

Meiji Seika patents two related series of progesterone receptor antagonists

Antagonists of NPY Y5 receptors reportedly useful for eating disorders, diabetes

Recent patents cover Roche's new lactam muscarinic receptor antagonists

Diazabicyclic nicotinic cholinergic receptor ligands designed at Targacept

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...